Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
According to research, shyness is defined as a fear and nervousness reaction to social novelty and/or social evaluation. Shyness can show up on the behavioral, affective, and physiological levels, but.
Read Full NewsThe U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, citing unresolved issues found at a...
The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.
Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.
1.
GLP-1 receptor agonists, cancer risk and questionable significance
2.
Benefits of perioperative radiotherapy for liver cancer with a high risk of recurrence are investigated in research.
3.
Pancreatic cancer RNA vaccine shows durable T cell immunity
4.
Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer
5.
Tipiracil hydrochloride and trifluridine tablets are approved by the USFDA for Natco Pharma.
1.
What Is Gastrinoma? Understanding This Rare Tumor and Its Treatment Options
2.
Minimal Residual Disease Monitoring: Advances, Clinical Relevance, and Guideline-Based Perspectives
3.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
4.
Exosomes in Cancer: A Novel Frontier for Therapy and Biomarker Discovery
5.
Breast Cancer Recovery: Fashion, Function, and Healing Beyond Scars
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge